JPMorgan Chase & Co. Sells 243,768 Shares of United Therapeutics Co. (UTHR)

JPMorgan Chase & Co. lessened its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 41.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 348,245 shares of the biotechnology company’s stock after selling 243,768 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.80% of United Therapeutics worth $44,533,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the company. Robeco Institutional Asset Management B.V. boosted its stake in United Therapeutics by 25.0% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 325,317 shares of the biotechnology company’s stock valued at $41,604,000 after buying an additional 65,049 shares in the last quarter. Fox Run Management L.L.C. boosted its stake in United Therapeutics by 85.2% in the 3rd quarter. Fox Run Management L.L.C. now owns 4,406 shares of the biotechnology company’s stock valued at $563,000 after buying an additional 2,027 shares in the last quarter. Acadian Asset Management LLC boosted its stake in United Therapeutics by 4.5% in the 3rd quarter. Acadian Asset Management LLC now owns 1,196,360 shares of the biotechnology company’s stock valued at $152,992,000 after buying an additional 51,346 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its stake in United Therapeutics by 3.1% in the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 559,107 shares of the biotechnology company’s stock valued at $63,263,000 after buying an additional 16,638 shares in the last quarter. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp boosted its stake in United Therapeutics by 18.9% in the 2nd quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 33,400 shares of the biotechnology company’s stock valued at $3,779,000 after buying an additional 5,300 shares in the last quarter. 93.69% of the stock is currently owned by institutional investors.

Several brokerages recently commented on UTHR. BidaskClub lowered United Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, September 24th. HC Wainwright set a $95.00 price target on United Therapeutics and gave the company a “hold” rating in a research note on Monday, August 13th. Barclays reaffirmed a “sell” rating and issued a $100.00 price target on shares of United Therapeutics in a research note on Thursday, August 2nd. Credit Suisse Group boosted their price target on United Therapeutics from $103.00 to $105.00 and gave the company a “sell” rating in a research note on Monday, November 19th. Finally, Cowen reiterated a “hold” rating and issued a $110.00 price objective on shares of United Therapeutics in a research report on Thursday, August 2nd. Two analysts have rated the stock with a sell rating, five have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $134.00.

In other United Therapeutics news, Director Christopher Causey sold 810 shares of United Therapeutics stock in a transaction on Monday, September 10th. The stock was sold at an average price of $119.00, for a total value of $96,390.00. Following the completion of the transaction, the director now owns 1,555 shares in the company, valued at approximately $185,045. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 8.20% of the company’s stock.

Shares of UTHR opened at $115.17 on Monday. The company has a quick ratio of 4.05, a current ratio of 4.32 and a debt-to-equity ratio of 0.09. United Therapeutics Co. has a 52-week low of $100.57 and a 52-week high of $152.55. The firm has a market capitalization of $5.02 billion, a price-to-earnings ratio of 10.58, a price-to-earnings-growth ratio of 26.88 and a beta of 1.23.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.23 by ($0.81). United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The business had revenue of $412.70 million during the quarter, compared to the consensus estimate of $378.22 million. During the same quarter in the previous year, the firm posted $4.69 EPS. The company’s revenue for the quarter was down 7.4% compared to the same quarter last year. On average, equities research analysts forecast that United Therapeutics Co. will post 14.28 earnings per share for the current year.

WARNING: “JPMorgan Chase & Co. Sells 243,768 Shares of United Therapeutics Co. (UTHR)” was originally posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.wkrb13.com/2018/11/26/jpmorgan-chase-co-sells-243768-shares-of-united-therapeutics-co-uthr.html.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Story: When is a capital gain realized?

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply